MODIFIED T CELLS AND METHODS OF MAKING AND USING THE SAME

Disclosed herein are modified primary human T cells and populations thereof comprising a genome in which the CTLA4, PD1, TCRA, TCRB, and/or B2M genes have been edited to generate an offthe-shelf universal CAR T cell from allogeneic healthy donors that can be administered to any patient while reducin...

Full description

Saved in:
Bibliographic Details
Main Authors MULUMBA, Kabungo, Y, MEISSNER, Torsten, B, FERREIRA, Leonardo, M., R, COWAN, Chad, A
Format Patent
LanguageEnglish
French
German
Published 01.11.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:Disclosed herein are modified primary human T cells and populations thereof comprising a genome in which the CTLA4, PD1, TCRA, TCRB, and/or B2M genes have been edited to generate an offthe-shelf universal CAR T cell from allogeneic healthy donors that can be administered to any patient while reducing or eliminating the risk of immune rejection or graft versus host disease, and which are not prone to T cell inhibition, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.
Bibliography:Application Number: EP20230187519